Investment in mRNA-based vaccines has dropped by 82% in 2025 compared to 2023 due to policy changes in the US. This decline is impacting R&D and funding for mRNA technology, shifting focus to mRNA-based drugs in oncology and infectious diseases.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing